Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition

Abstract

Introduction: Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain unexplained by genomic properties. Emerging evidence shows that receptor tyrosine kinase (RTK) reprogramming is a major alternative process causing targeted drug resistance, separate from genetic alterations. Hence, the contributions of mechanisms leading to this process need to be more rigorously assessed.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 26, 2018
Accession Number
AD1083385

Entities

People

  • Aaron S. Meyer
  • Allison M. Claas
  • Douglas A. Lauffenburger
  • Lyla Atta
  • Simon Gordonov

Organizations

  • Massachusetts Institute of Technology

Tags

DTIC Thesaurus Topics

  • Algorithms
  • Bioengineering
  • Biological Factors
  • Breast Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Computer Vision
  • Data Science
  • Experimental Data
  • Genetics
  • Lung Cancer
  • Lymphatic Diseases
  • Neoplasms
  • Proteins
  • Therapy

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Molecular Biology and Genetics
  • Systems Analysis and Design

Technology Areas

  • Biotechnology